NZ595433A - 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 - Google Patents
4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2Info
- Publication number
- NZ595433A NZ595433A NZ595433A NZ59543310A NZ595433A NZ 595433 A NZ595433 A NZ 595433A NZ 595433 A NZ595433 A NZ 595433A NZ 59543310 A NZ59543310 A NZ 59543310A NZ 595433 A NZ595433 A NZ 595433A
- Authority
- NZ
- New Zealand
- Prior art keywords
- methyl
- ylcarbamoyl
- azetidin
- benzamide
- trifluoromethyl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000011580 syndromic disease Diseases 0.000 abstract 3
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000002975 chemoattractant Substances 0.000 abstract 1
- 102000003675 cytokine receptors Human genes 0.000 abstract 1
- 108010057085 cytokine receptors Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- DPCUJUSPJRBELZ-UHFFFAOYSA-N n-[2-[[1-[4-(1,3-benzodioxol-5-ylcarbamoylamino)cyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCC(=O)NC2CN(C2)C2CCC(CC2)NC(=O)NC=2C=C3OCOC3=CC=2)=C1 DPCUJUSPJRBELZ-UHFFFAOYSA-N 0.000 abstract 1
- OEKTZWKCHPJLMT-UHFFFAOYSA-N n-[2-[[1-[4-(2,5-dimethylpyrrol-1-yl)cyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound CC1=CC=C(C)N1C1CCC(N2CC(C2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 OEKTZWKCHPJLMT-UHFFFAOYSA-N 0.000 abstract 1
- OEDILMILNVRNIQ-UHFFFAOYSA-N n-[2-[[1-[4-(4-iodopyrazol-1-yl)cyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCC(=O)NC2CN(C2)C2CCC(CC2)N2N=CC(I)=C2)=C1 OEDILMILNVRNIQ-UHFFFAOYSA-N 0.000 abstract 1
- YHKVPWCTDDFFFY-UHFFFAOYSA-N n-[2-[[1-[4-(4-methylpyridin-2-yl)oxycyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound CC1=CC=NC(OC2CCC(CC2)N2CC(C2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)=C1 YHKVPWCTDDFFFY-UHFFFAOYSA-N 0.000 abstract 1
- KSIDEJORWQRBEU-UHFFFAOYSA-N n-[2-[[1-[4-(5-methylpyridin-2-yl)oxycyclohexyl]azetidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide Chemical compound N1=CC(C)=CC=C1OC1CCC(N2CC(C2)NC(=O)CNC(=O)C=2C=C(C=CC=2)C(F)(F)F)CC1 KSIDEJORWQRBEU-UHFFFAOYSA-N 0.000 abstract 1
- NAWWABAQSDGYPX-UHFFFAOYSA-N n-[2-oxo-2-[[1-(4-pyrimidin-4-yloxycyclohexyl)azetidin-3-yl]amino]ethyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=CC=CC(C(=O)NCC(=O)NC2CN(C2)C2CCC(CC2)OC=2N=CN=CC=2)=C1 NAWWABAQSDGYPX-UHFFFAOYSA-N 0.000 abstract 1
- JCCGSOVTBIJRGP-UHFFFAOYSA-N n-piperidin-1-ylprop-2-enamide Chemical class C=CC(=O)NN1CCCCC1 JCCGSOVTBIJRGP-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17022509P | 2009-04-17 | 2009-04-17 | |
| PCT/US2010/031255 WO2010121036A1 (en) | 2009-04-17 | 2010-04-15 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ595433A true NZ595433A (en) | 2013-12-20 |
Family
ID=42169493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ595433A NZ595433A (en) | 2009-04-17 | 2010-04-15 | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8324186B2 (OSRAM) |
| EP (1) | EP2419418B1 (OSRAM) |
| JP (1) | JP5685581B2 (OSRAM) |
| KR (1) | KR20120006051A (OSRAM) |
| CN (1) | CN102459226B (OSRAM) |
| AR (1) | AR076329A1 (OSRAM) |
| AU (1) | AU2010236336B2 (OSRAM) |
| BR (1) | BRPI1016205A2 (OSRAM) |
| CA (1) | CA2758929A1 (OSRAM) |
| ES (1) | ES2541607T3 (OSRAM) |
| MX (1) | MX2011010963A (OSRAM) |
| NZ (1) | NZ595433A (OSRAM) |
| TW (1) | TW201102379A (OSRAM) |
| WO (1) | WO2010121036A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2745969C (en) | 2008-12-10 | 2017-04-25 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| KR20120061060A (ko) * | 2009-04-16 | 2012-06-12 | 얀센 파마슈티카 엔.브이. | Ｃｃｒ2의 4-아제티디닐-1-헤테로아릴-사이클로헥산 길항제 |
| MX2011010963A (es) | 2009-04-17 | 2011-11-02 | Janssen Pharmaceutica Nv | Antagonistas del receptor 2 de citocina quimiotrayente de ciclohexano unido al 4-azetidinil-1-heteroatomo. |
| CN102459227B (zh) * | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
| TW201211027A (en) * | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| AU2011268375B2 (en) | 2010-06-17 | 2015-02-05 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
| EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
| EP3059225A4 (en) * | 2013-10-17 | 2017-09-06 | Shionogi & Co., Ltd. | Novel alkylene derivative |
| US20230174633A1 (en) * | 2020-03-30 | 2023-06-08 | Memorial Sloan Kettering Cancer Center | Methods and compositions for modulating lipid storage in adipose tissue |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6037354A (en) * | 1997-06-18 | 2000-03-14 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| AU734892B2 (en) | 1997-06-18 | 2001-06-28 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| CN1192773C (zh) | 1999-08-04 | 2005-03-16 | 帝人株式会社 | 环胺ccr3拮抗剂 |
| US6245799B1 (en) * | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| WO2001034598A1 (en) | 1999-11-08 | 2001-05-17 | Wyeth | [(indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
| WO2002060859A2 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| UA87449C2 (ru) * | 2002-11-27 | 2009-07-27 | Инсайт Корпорейшн | Производные 3-аминопиролидина как модуляторы рецепторов хемокина |
| AU2003293129B2 (en) * | 2002-11-27 | 2009-03-12 | Incyte Holdings Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| GB0417801D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
| WO2006036527A1 (en) * | 2004-09-28 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Substituted dipiperdine ccr2 antagonists |
| UY29219A1 (es) * | 2004-11-22 | 2006-04-28 | Incyte Corp | Sales de la n-(2- (((3r)-1-(trans-4-hidroxi-4-(6-metoxipiridin-3-il)-cilohexil) pirrolidin-3-il)amino)-2-oxoetil)-3- (trifluorometil) benzamida |
| GB0513747D0 (en) | 2005-07-06 | 2005-08-10 | Merck Sharp & Dohme | Therapeutic compounds |
| US8067457B2 (en) | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| US20070197590A1 (en) | 2006-01-31 | 2007-08-23 | Demong Duane E | Substituted dipiperidine ccr2 antagonists |
| JP2011506466A (ja) * | 2007-12-11 | 2011-03-03 | 株式会社サイトパスファインダー | カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用 |
| CA2745969C (en) * | 2008-12-10 | 2017-04-25 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 |
| KR20120061060A (ko) * | 2009-04-16 | 2012-06-12 | 얀센 파마슈티카 엔.브이. | Ｃｃｒ2의 4-아제티디닐-1-헤테로아릴-사이클로헥산 길항제 |
| MX2011010963A (es) | 2009-04-17 | 2011-11-02 | Janssen Pharmaceutica Nv | Antagonistas del receptor 2 de citocina quimiotrayente de ciclohexano unido al 4-azetidinil-1-heteroatomo. |
| CN102459227B (zh) | 2009-04-17 | 2014-08-20 | 詹森药业有限公司 | Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂 |
-
2010
- 2010-04-15 MX MX2011010963A patent/MX2011010963A/es active IP Right Grant
- 2010-04-15 BR BRPI1016205A patent/BRPI1016205A2/pt not_active Application Discontinuation
- 2010-04-15 EP EP10714151.7A patent/EP2419418B1/en active Active
- 2010-04-15 CN CN201080027621.9A patent/CN102459226B/zh not_active Expired - Fee Related
- 2010-04-15 AU AU2010236336A patent/AU2010236336B2/en not_active Ceased
- 2010-04-15 JP JP2012506227A patent/JP5685581B2/ja not_active Expired - Fee Related
- 2010-04-15 US US12/760,855 patent/US8324186B2/en not_active Expired - Fee Related
- 2010-04-15 ES ES10714151.7T patent/ES2541607T3/es active Active
- 2010-04-15 NZ NZ595433A patent/NZ595433A/en not_active IP Right Cessation
- 2010-04-15 CA CA2758929A patent/CA2758929A1/en not_active Abandoned
- 2010-04-15 KR KR1020117026820A patent/KR20120006051A/ko not_active Withdrawn
- 2010-04-15 WO PCT/US2010/031255 patent/WO2010121036A1/en not_active Ceased
- 2010-04-16 TW TW099111900A patent/TW201102379A/zh unknown
- 2010-04-19 AR ARP100101288A patent/AR076329A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010236336B2 (en) | 2015-01-15 |
| KR20120006051A (ko) | 2012-01-17 |
| AU2010236336A1 (en) | 2011-11-03 |
| WO2010121036A1 (en) | 2010-10-21 |
| JP2012524110A (ja) | 2012-10-11 |
| MX2011010963A (es) | 2011-11-02 |
| CN102459226B (zh) | 2014-09-17 |
| US20100267668A1 (en) | 2010-10-21 |
| US8324186B2 (en) | 2012-12-04 |
| CA2758929A1 (en) | 2010-10-21 |
| CN102459226A (zh) | 2012-05-16 |
| TW201102379A (en) | 2011-01-16 |
| AR076329A1 (es) | 2011-06-01 |
| EP2419418A1 (en) | 2012-02-22 |
| JP5685581B2 (ja) | 2015-03-18 |
| EP2419418B1 (en) | 2015-04-15 |
| BRPI1016205A2 (pt) | 2016-04-19 |
| ES2541607T3 (es) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ595433A (en) | 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2 | |
| PL2029529T3 (pl) | PODSTAWIONE PIROLIDYNONY JAKO INHIBITORY DEHYDROGENAZY 11-ß-HYDROKSYSTEROIDOWEJ TYPU 1 | |
| ES2318577T3 (es) | Derivados de cicloalquil lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1'. | |
| ATE455110T1 (de) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| ZA200808816B (en) | Pieridinyl substituted pyrrolidinones as inhibitors of 11-Beta-hydroxysteroid dehydrogenase 1 | |
| ATE472542T1 (de) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| ATE471311T1 (de) | Inhibitoren von11-beta- hydroxysteroiddehydrogenase 1 | |
| JO3042B1 (ar) | مشتقات السيكلوبيرازول-لاكتام كمثبطات لل 11-بيتا-هيدروكسي ستيرويد داي هيدروجينيز 1 | |
| EA200870472A1 (ru) | Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1 | |
| UA96764C2 (ru) | Производные бензимидазола, полезные в лечении расстройств, связанных с рецептором trpvl | |
| MX2009005363A (es) | Pirimidinas y su uso como antagonistas del receptor cxcr2. | |
| NZ594597A (en) | Substituted piperidines as ccr3 antagonists | |
| NZ595432A (en) | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 | |
| ATE476418T1 (de) | Benzamidderivate und assoziierte verwendungen | |
| ATE484505T1 (de) | 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten | |
| MX2010012189A (es) | Derivados de quinuclidina como antagonistas del receptor m3 muscarinico. | |
| MX2012004112A (es) | Derivados de diazepam como moduladores de los receptores de quimiocina. | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| NZ584998A (en) | Cycloalkyloxy-and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor | |
| ATE450503T1 (de) | Pyrrolidinderivate als histamin-h3- rezeptorantagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 APR 2017 BY CPA GLOBAL Effective date: 20140602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 APR 2020 BY CPA GLOBAL Effective date: 20140906 |
|
| LAPS | Patent lapsed |